{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:54:17Z","timestamp":1783976057908,"version":"3.55.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ijcard.2014.08.086","type":"journal-article","created":{"date-parts":[[2014,9,6]],"date-time":"2014-09-06T16:06:58Z","timestamp":1410019618000},"page":"640-644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Muscle wasting: An overview of recent developments in basic research"],"prefix":"10.1016","volume":"176","author":[{"given":"Sandra","family":"Palus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Springer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2014.08.086_bb0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s13539-013-0111-0","article-title":"Why cachexia kills: examining the causality of poor outcomes in wasting conditions","volume":"4","author":"Kalantar-Zadeh","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13539-012-0089-z","article-title":"From muscle wasting to sarcopenia and myopenia: update 2012","volume":"3","author":"von Haehling","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13539-013-0124-8","article-title":"Cachexia vs obesity: where is the real unmet clinical need?","volume":"4","author":"von Haehling","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s13539-013-0105-y","article-title":"Cachexia as a major public health problem: frequent, costly, and deadly","volume":"4","author":"Farkas","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin Nutr"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13539-010-0002-6","article-title":"Cachexia as a major underestimated and unmet medical need: facts and numbers","volume":"1","author":"von Haehling","year":"2010","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13539-010-0014-2","article-title":"An overview of sarcopenia: facts and numbers on prevalence and clinical impact","volume":"1","author":"von Haehling","year":"2010","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0040","doi-asserted-by":"crossref","first-page":"M772","DOI":"10.1093\/gerona\/57.12.M772","article-title":"Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women","volume":"57","author":"Iannuzzi-Sucich","year":"2002","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fphys.2014.00099","article-title":"Skeletal muscle wasting with disuse atrophy is multi-dimensional: the response and interaction of myonuclei, satellite cells and signaling pathways","volume":"5","author":"Brooks","year":"2014","journal-title":"Front Physiol"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0050","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.biocel.2013.06.024","article-title":"Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials","volume":"45","author":"Marzetti","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0055","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s13539-012-0068-4","article-title":"Role and potential mechanisms of anabolic resistance in sarcopenia","volume":"3","author":"Haran","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0060","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s13539-013-0123-9","article-title":"Abstracts of the 7th cachexia conference, kobe\/osaka, Japan, december 9\u201311, 2013","volume":"4","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13539-014-0129-y","article-title":"Abstracts of the 7th cachexia conference, kobe\/osaka, Japan, december 9\u201311, 2013 (part 2)","volume":"5","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13539-012-0087-1","article-title":"Cancer cachexia: impact, mechanisms and emerging treatments","volume":"4","author":"Vaughan","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s13539-011-0043-5","article-title":"Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia","volume":"2","author":"Trobec","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0080","doi-asserted-by":"crossref","first-page":"E700","DOI":"10.1210\/jc.2011-2387","article-title":"Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia","volume":"97","author":"Burney","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3892\/ol.2011.442","article-title":"Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats","volume":"3","author":"Busquets","year":"2012","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0090","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13539-010-0011-5","article-title":"Ghrelin for cachexia","volume":"1","author":"Akamizu","year":"2010","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0095","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2044-5040-1-4","article-title":"Regulation of skeletal muscle growth by the IGF1-Akt\/PKB pathway: insights from genetic models","volume":"1","author":"Schiaffino","year":"2011","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13539-012-0065-7","article-title":"Hypogonadism in male cancer patients","volume":"3","author":"Burney","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13539-011-0034-6","article-title":"The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial","volume":"2","author":"Dalton","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0110","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/eurheartj\/eht302","article-title":"Prevention of liver cancer cachexia-induced cardiac wasting and heart failure","volume":"35","author":"Springer","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s13539-012-0062-x","article-title":"Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia","volume":"3","author":"Pedroso","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13539-011-0047-1","article-title":"The effect of exercise on IL-6-induced cachexia in the Apc ( Min\/+) mouse","volume":"3","author":"Puppa","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0125","doi-asserted-by":"crossref","first-page":"e30276","DOI":"10.1371\/journal.pone.0030276","article-title":"Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy","volume":"7","author":"Rezk","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0130","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijcard.2013.10.022","article-title":"Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia","volume":"170","author":"Elkina","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0135","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/jjco\/hys238","article-title":"Hypomanic episode as a first presentation of a large B-cell lymphoma","volume":"43","author":"Olde Engberink","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0140","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13539-011-0035-5","article-title":"The role of myostatin in muscle wasting: an overview","volume":"2","author":"Elkina","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/10409238.2013.857291","article-title":"Signaling pathways controlling skeletal muscle mass","volume":"49","author":"Egerman","year":"2014","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0150","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13539-011-0049-z","article-title":"Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance","volume":"3","author":"Busquets","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2044-5040-2-2","article-title":"TNF-alpha- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism","volume":"2","author":"De Larichaudy","year":"2012","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0165","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cmet.2011.01.001","article-title":"Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle","volume":"13","author":"Shimizu","year":"2011","journal-title":"Cell Metab"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0170","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s13539-012-0101-7","article-title":"Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia","volume":"4","author":"Der-Torossian","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0175","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s13539-011-0052-4","article-title":"Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass","volume":"3","author":"Sakuma","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2044-5040-2-3","article-title":"TAK-1\/p38\/nNFkappaB signaling inhibits myoblast differentiation by increasing levels of Activin A","volume":"2","author":"Trendelenburg","year":"2012","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0185","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MCO.0b013e32833862df","article-title":"Signaling pathways perturbing muscle mass","volume":"13","author":"Glass","year":"2010","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0190","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/emboj.2008.52","article-title":"The initiation factor eIF3-f is a major target for atrogin1\/MAFbx function in skeletal muscle atrophy","volume":"27","author":"Lagirand-Cantaloube","year":"2008","journal-title":"EMBO J"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0195","doi-asserted-by":"crossref","first-page":"e4973","DOI":"10.1371\/journal.pone.0004973","article-title":"Inhibition of atrogin-1\/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo","volume":"4","author":"Lagirand-Cantaloube","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0200","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1083\/jcb.200901052","article-title":"During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation","volume":"185","author":"Cohen","year":"2009","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0205","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1083\/jcb.201110067","article-title":"Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy","volume":"198","author":"Cohen","year":"2012","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2044-5040-3-11","article-title":"Trip12, a HECT domain E3 ubiquitin ligase, targets Sox6 for proteasomal degradation and affects fiber type-specific gene expression in muscle cells","volume":"3","author":"An","year":"2013","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0215","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1096\/fj.12-222844","article-title":"Diaphragm and ventilatory dysfunction during cancer cachexia","volume":"27","author":"Roberts","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0220","doi-asserted-by":"crossref","first-page":"42394","DOI":"10.1074\/jbc.C200444200","article-title":"SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2","volume":"277","author":"Rui","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0225","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1128\/MCB.01347-08","article-title":"Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading","volume":"29","author":"Nakao","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0230","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.molcel.2008.03.009","article-title":"The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation","volume":"30","author":"Xu","year":"2008","journal-title":"Mol Cell"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0235","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.4161\/cc.7.20.6922","article-title":"The cullin7 E3 ubiquitin ligase: a novel player in growth control","volume":"7","author":"Sarikas","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0240","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.devcel.2011.09.011","article-title":"The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling","volume":"21","author":"Shi","year":"2011","journal-title":"Dev Cell"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0245","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nature11834","article-title":"Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders","volume":"494","author":"Song","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0250","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13539-011-0051-5","article-title":"The role of insulin resistance in the development of muscle wasting during cancer cachexia","volume":"3","author":"Honors","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0255","doi-asserted-by":"crossref","DOI":"10.1007\/s13539-014-0145-y","article-title":"Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?","author":"Fogelman","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0260","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s13539-011-0029-3","article-title":"IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia","volume":"2","author":"Schmidt","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0265","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s13539-013-0113-y","article-title":"A pilot study of temsirolimus and body composition","volume":"4","author":"Veasey-Rodrigues","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0270","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.biocel.2013.05.019","article-title":"Myostatin\/activin pathway antagonism: molecular basis and therapeutic potential","volume":"45","author":"Han","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0275","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/emboj.2010.60","article-title":"Mitochondrial fission and remodelling contributes to muscle atrophy","volume":"29","author":"Romanello","year":"2010","journal-title":"EMBO J"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0280","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cmet.2012.10.005","article-title":"The ubiquitin ligase Mul1 induces mitophagy in skeletal muscle in response to muscle-wasting stimuli","volume":"16","author":"Lokireddy","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0285","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13539-012-0073-7","article-title":"Effect of colon cancer and surgical resection on skeletal muscle mitochondrial enzyme activity in colon cancer patients: a pilot study","volume":"4","author":"Phillips","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0290","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13539-012-0071-9","article-title":"Cancer cachexia is associated with a decrease in skeletal muscle mitochondrial oxidative capacities without alteration of ATP production efficiency","volume":"3","author":"Julienne","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0295","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1741-7007-11-12","article-title":"MST1, a key player, in enhancing fast skeletal muscle atrophy","volume":"11","author":"Wei","year":"2013","journal-title":"BMC Biol"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0300","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s13539-012-0082-6","article-title":"Anorexia\/cachexia of chronic diseases: a role for the TGF-beta family cytokine MIC-1\/GDF15","volume":"3","author":"Tsai","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0305","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1016\/j.ijcard.2013.01.263","article-title":"Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model","volume":"168","author":"Palus","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0310","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13539-012-0085-3","article-title":"Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model","volume":"4","author":"Lenk","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0315","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1249\/00005768-199508000-00003","article-title":"Clenbuterol: a substitute for anabolic steroids?","volume":"27","author":"Prather","year":"1995","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0320","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13539-011-0018-6","article-title":"Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration?","volume":"2","author":"Toledo","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0325","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00520-013-2081-3","article-title":"Phase I\/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy","volume":"22","author":"Greig","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0330","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00555.2011","article-title":"cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration","volume":"303","author":"Berdeaux","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0335","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/ncb2404","article-title":"Wnt7a-Fzd7 signalling directly activates the Akt\/mTOR anabolic growth pathway in skeletal muscle","volume":"14","author":"von Maltzahn","year":"2012","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0340","doi-asserted-by":"crossref","first-page":"ra80","DOI":"10.1126\/scisignal.2002038","article-title":"Galphai2 signaling promotes skeletal muscle hypertrophy, myoblast differentiation, and muscle regeneration","volume":"4","author":"Minetti","year":"2011","journal-title":"Sci Signal"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0345","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s13539-012-0081-7","article-title":"Finding good biomarkers for sarcopenia","volume":"3","author":"Scharf","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0350","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s13539-012-0078-2","article-title":"Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia","volume":"3","author":"Cesari","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13539-012-0086-2","article-title":"Serological muscle loss biomarkers: an overview of current concepts and future possibilities","volume":"4","author":"Nedergaard","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0360","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1210\/jc.2009-1434","article-title":"N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone","volume":"94","author":"Bhasin","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0365","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13539-011-0021-y","article-title":"Evaluation of early biomarkers of muscle anabolic response to testosterone","volume":"2","author":"Chen","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0370","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s13539-013-0114-x","article-title":"Type VI collagen turnover-related peptides-novel serological biomarkers of muscle mass and anabolic response to loading in young men","volume":"4","author":"Nedergaard","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0375","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12020-012-9836-3","article-title":"Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status","volume":"43","author":"Christensen","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0380","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3390\/metabo3040931","article-title":"The complex role of branched chain amino acids in diabetes and cancer","volume":"3","author":"O'Connell","year":"2013","journal-title":"Metabolites"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0385","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13539-012-0079-1","article-title":"Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature","volume":"4","author":"Patel","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0390","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1152\/japplphysiol.00122.2012","article-title":"Total-body creatine pool size and skeletal muscle mass determination by creatine-(methyl-D3) dilution in rats","volume":"112","author":"Stimpson","year":"2012","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0395","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1152\/japplphysiol.00045.2014","article-title":"Total body skeletal muscle mass: estimation by creatine (methyl-d3) dilution in humans","volume":"116","author":"Clark","year":"2014","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.ijcard.2014.08.086_bb0400","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13539-013-0110-1","article-title":"Longitudinal changes in total body creatine pool size and skeletal muscle mass using the D-creatine dilution method","volume":"4","author":"Stimpson","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314016313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314016313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T18:50:11Z","timestamp":1565808611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527314016313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0167527314016313"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.08.086","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Muscle wasting: An overview of recent developments in basic research","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.08.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}